Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors08/07/2024PR Newswire
Mainland China-Hong Kong ETF Connect Marks Two Years of Strengthened Market Integration, Expansion Expected to Boost Investment Options and Liquidity08/07/2024PR Newswire
Advancing Its Plan Towards Net Zero, Vinamilk Announces Third Carbon Neutral Facility08/07/2024PR Newswire
MARRIOTT BONVOY DELIVERS EXTRAORDINARY MOMENTS WITH THE MERCEDES-AMG PETRONAS F1 TEAM IN SINGAPORE08/07/2024PR Newswire
Parents: Discover the Three Essential Pillars of Childcare for Your Child’s Optimal Development08/07/2024PR Newswire
Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics08/07/2024PR Newswire
Above the Sky: Sino Jet Partners with Kaluga Queen Caviar to Lead a Life of Exquisite Elegance08/07/2024PR Newswire
